Omicron subvariants BQ.1.1 and BQ.1, which knocked down the last monoclonal antibody treatment to be authorized for COVID-19, now account for 62.8 percent of COVID-19 cases, according to the CDC.
Read the full post on Becker's Hospital Review - Healthcare News
